0:00
Hello, everybody.
I'm Matthias von Herrath, and I'm
a professor at La Jolla Institute,
and also a vice present
for Novo Nordisk
for an approach that develops
therapeutics for type 1 diabetes.
We'll be talking about the value
and limitation of mouse models
in general today, but I will
construct the talk with an area
that I know best, which is the
development of immune therapies
for type 1 diabetes.
And these examples I will give
you in the course of the talk
should hopefully also be very
useful for the use of animal models
in other therapeutic areas.
0:45
It's a timely situation because,
especially in diabetes, but also
in other applications of
biology, there has always
been a lot of controversy
surrounding the use of animal
models, whether they
reflect the human situation,
whether they don't reflect
the human situation,
when they reflect
the human situation.
And really, what you
will see from the talk,
and as my position on
this whole subject,
is that it's very valuable to use
animal models, and in this case
mouse models, which we will
be talking about today,
if they are used in
the correct fashion.
And hopefully from the ensuing talk,
you can gather some advice on how
this can be done, and
also to realize that it's
very important in the
design of experiments
and in the whole translation
of the process from animal
models to the human bedside to
know the limitation of such animal
models.
I should also add that
I will not discuss,
because I also work for a
pharmaceutical company, Novo
Nordisk, I will not discuss
any drugs or approaches
from Novo Nordisk that are
specific for the company,
and that will be my disclaimer.
